Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BCAB
- Price
- 0.40
- Stock movement down
- -0.02 (-4.72%)
- Company name
- Bioatla Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 21.00M
- Ent value
- 3.75M
- Price/Sales
- 1.65
- Price/Book
- 0.91
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -81.18%
- 3 year return
- -68.88%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
BCAB does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.65 |
| Price to Book | 0.91 |
| EV to Sales | 0.30 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 58.72M |
| EPS (TTM) | -1.69 |
| FCF per share (TTM) | -1.76 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 12.71M |
| Gross profit (TTM) | 11.87M |
| Operating income (TTM) | -86.23M |
| Net income (TTM) | -81.82M |
| EPS (TTM) | -1.69 |
| EPS (1y forward) | -1.20 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 93.41% |
| Operating margin (TTM) | -678.70% |
| Profit margin (TTM) | -643.92% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 56.52M |
| Net receivables | 0.00 |
| Total current assets | 60.57M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 62.24M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 1.25M |
| Total current liabilities | 19.46M |
| Total liabilities | 39.27M |
| Shareholder's equity | 22.97M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -85.08M |
| Capital expenditures (TTM) | 8.00K |
| Free cash flow (TTM) | -85.08M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -356.22% |
| Return on Assets | -131.46% |
| Return on Invested Capital | -337.82% |
| Cash Return on Invested Capital | -351.31% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.38 |
| Daily high | 0.38 |
| Daily low | 0.35 |
| Daily Volume | 412K |
| All-time high | 70.91 |
| 1y analyst estimate | 10.00 |
| Beta | 0.89 |
| EPS (TTM) | -1.69 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 Nov 2025 |
Downside potential
Loading...
Downside potential data
| BCAB | S&P500 | |
| Current price drop from All-time high | -99.50% | -1.46% |
| Highest price drop | -99.62% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -82.26% | -10.99% |
| Avg time to new high | 47 days | 12 days |
| Max time to new high | 1113 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
21.00M
Marketcap category
Small-cap
Description
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Employees
61
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page